Twist Bioscience preliminary Q1 FY2026 revenue ~$103.7M, up 17% YoY, ahead of guidance

Twist Bioscience Corp

2026-Q1 EPS reported -$0.50 revenue$103,698,000

Preliminary Q1 FY2026 revenue ~$103.7M (+/- $0.2M), 17% YoY growth, above guidance of $100-101M.
DNA Synthesis & Protein Solutions revenue $51.1M (+/- $0.1M), up 27% YoY.
NGS Applications revenue $52.6M (+/- $0.1M), ahead of guidance; excluding one customer transition, NGS grew 18% YoY.
Full Q1 financial results to be reported on Feb 2, 2026, before market open.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.